This article is the second in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn's disease. The first article covers medical management; the present article addresses surgical management, including preoperative aspects and drug management before surgery. It also provides technical advice for a variety of common clinical situations. Both articles together represent the evidence-based recommendations of the ECCO for Crohn's disease and an update of prior guidelines.
Introduction
The incidence and prevalence of Crohn's disease [CD] is rising globally, with yearly increases in incidence ranging from 4-15% over the last three decades 1 . A cure remains elusive and efficient management of CD is essentially multidisciplinary and interprofessional. At least half of patients with CD undergo one or more surgical procedures during their lifetime. CD patients frequently suffer from malnutrition, psychological comorbidities, and may have to live with a stoma [2] [3] [4] [5] . Care for CD has become more complex for both medical and surgical disciplines. Several new drugs have entered the market and surgical subspecialization for inflammatory bowel disease has evolved. The best possible outcomes are currently achieved within dedicated expert centres providing personalized medicine [6] [7] [8] [9] [10] . Care for CD is exemplary in an interrelated clinical world where the actions of individual health care providers need coordination, common knowledge, and shared expectations to optimize clinical management and research in terms of diagnosis, treatment, and side-effects. The European Crohn's and Colitis Organisation [ECCO] provides an interdisciplinary framework with the present evidence-based consensus guidelines to inform and guide clinicians and allied health care providers caring for patients with CD. The present guidelines focus on surgery for CD, including preoperative aspects and drug management before surgery, and provide technical advice for a variety of common clinical presentations. Further guidance on most aspects of interdisciplinary and interprofessional care for CD has been elaborated by ECCO in separate publications 3, [11] [12] [13] [14] [15] [16] .
Methods
A detailed description of the methodology used is presented in the supplementary materials. This article is the second in a series of two publications relating to the ECCO evidence-based consensus on the management of CD. The first article [Torres J et al ECCO guidelines on therapeutics in CD, JCC 2020 in press] covered medical management; the present article addresses surgical management. Both articles together represent the evidence-based recommendations of the ECCO for CD and update prior guidelines published in 2016 17, 18 . These guidelines abide by the GRADE methodology in terms of framing clinically relevant questions to draw evidence-based statements and recommendations. However, due to the peculiarities of the surgical 19 . This allowed us to formulate statements and practice recommendations that can be operationalized and can guide clinical management. No randomized controlled trials [RCT] or prospective studies were found that compared anti-TNF treatment alone versus anti-TNF and surgery combined to treat complex perianal CD fistulae. A heterogeneous group of retrospective studies that compared anti-TNF treatment with a variety of surgical approaches was combined in a meta-analysis published in 2014 20 . The results of this analysis suggest that combined treatment "may have additional beneficial effects compared to surgical or medical treatment alone". However, the heterogeneity of the included studies, the retrospective nature of the included analysis, and low study quality preclude any firm conclusions or recommendations. Recently, results of the PISA study were presented as an abstract 21 . PISA randomized patients with high perianal CD fistula and a single internal opening initially drained for 6 weeks to chronic seton drainage or anti-TNF for one year or advancement plasty under anti-TNF for 4 months. Primary outcome was fistula- In practice, management decisions remain with the physician and surgeon, considering clinical information and any resource implications. The key role of surgery is in controlling perianal sepsis by examination under anaesthesia and appropriate seton drainage. In this regard, successful medical therapy and minimizing the risk of anti-TNF therapy depends upon a close liaison between the physician and surgeon.
According to the summary of product characteristics registered and approved by the regulatory agencies, active sepsis or any infection is a clear contraindication to the use of infliximab or adalimumab. Therefore, any procedure likely to treat and prevent perianal sepsis is recommended as good clinical practice and must be performed swiftly in the presence of signs of infection.
Surgical techniques

Statement 1.2 ECCO CD Treatment GL [2019]
Advancement flaps are a therapeutic option for patients with Crohn´s disease and complex perianal fistulae [EL4]
A systematic review identified 11 retrospective studies that reported data from 135 patients with CD perianal fistulae treated with an advancement flap 22 . The pooled success rate was 66%. However, definitions of success and length of follow-up were highly variable, the results were heterogeneous, and the overall evidence level was low. In a more recent meta-analysis, Stellingwerf et al. observed a 61% success rate in 35 patients with CD perianal fistula, which did not differ significantly from the success rate of a ligation of the intersphincteric fistula tract [LIFT] procedure [53%]. However, incontinence rates were significantly higher after flaps [7.8% versus 1.6%] 23 .
As a RCT comparing advancement flap to no surgery would be unethical, collaborative efforts to collect larger numbers of cases undergoing advancement flap for perianal CD, with defined outcomes and follow-up, are required to better define the role of this technique in CD. 
Statement 1.3 ECCO CD Treatment GL [2019]
Fibrin glue may be a potential treatment with limited efficacy for patients with complex perianal Crohn's disease [EL4]
The use of fibrin glue for the treatment of CD perianal fistulae was assessed in an open-label RCT with 71 patients randomized to instillation of fibrin glue into the fistula tract or no further treatment after removal of seton 24 . Overall clinical remission rates at week 8 were 38% for fibrin glue and 16% in the observation group [p = 0.04]. There was no significant difference in adverse events, which were non-significantly higher in the observation group. Follow-up length in this RCT was insufficient for a definitive judgement on the true success rate. Several cohort studies with small numbers of CD patients reported a wide range of success rates with fibrin glue treatment. A uniform characteristic of all these studies is the relatively good safety profile of this technique, with no reported injury to the sphincter muscles, which may potentially justify attempting this technique in cognizant patients 25 .
Statement 1.4 ECCO CD Treatment GL [2019]
Ligation of the intersphincteric fistula tract is an option for treatment of patients with
Crohn's disease and complex perianal fistulae [EL4]
LIFT is a recent option in the armamentarium of surgical treatments for perianal fistulae. Sirany et al. performed a systematic literature review and identified 26 studies that included a total of 713 patients, of which 13 had CD 26 . Among these studies was a single RCT (which however excluded CD patients) and 25 cohort or case series.
Studies were heterogeneous with a wide range of outcome measures and follow-up times. The techniques used were only partially described and included seven technical variations. Primary healing rates ranged from 47-95%, thus even the lower end of this 
Statement 1.5 ECCO CD Treatment GL [2019]
Anal Fistula Plugs (AFP) should not be routinely considered for ano-perineal fistulas closure in Crohn's disease, as seton removal alone is equally effective [EL3]
The use of collagen anal fistula plug [AFP] in patients with CD perianal fistulae was assessed in a single RCT, which compared seton removal with insertion of AFP into the fistula tract to seton removal and observation only in 106 CD patients 29 . After 12 weeks, the fistula closure rate in the AFP group was 33.3% in patients with complex fistulae and 30.7% in patients with simple fistulae, as compared with 15.4% and 25.6% with seton removal alone, respectively. These differences were not statistically significant, perhaps because of an underpowered trial design. Importantly, there was a trend towards more adverse events at 12 weeks in the AFP group [17% vs. 8%; p = 0.07]. However, cumulative adverse event rates at 12 months follow-up were similar.
A systematic review of 12 observational studies included 84 patients with a median follow-up time of 9 [3-24] months 30 . The overall fistula closure rate was 58.3%, with 40% success in the very small subgroup with a recurrent anal fistula from previous treatments. However, there was no uniform definition for fistula closure or follow-up regimen. The quality of evidence for this systematic review was rated low due to the risk of bias and imprecision.
In the three largest studies that included both CD fistulae and non-CD fistulae [31] [32] [33] , the overall healing rate for CD fistulae was 47.0% versus 72.2% for non-CD fistulae.
Repeating the plug procedure produced a lower success rate. Finally, a RCT that excluded CD compared 48 patients treated with a plug to 46 patients treated with an The use of AFP in patients with CD appears to be relatively safe and may be considered for selected patients aware of the low success rate. A meta-analysis of 11 studies, including 3 RCTs of which the ADMIRE CD was the largest 38 , showed improved healing rates when compared to the control arms.
Allogeneic stem cell therapy seems to be safe. In the ADMIRE CD trial, serious adverse events did not significantly differ between the two groups, although the adverse event rate, mainly abscesses and fistulae, was slightly and not significantly higher in the treatment group compared with placebo [24.3% vs. to 20.6%]. There are currently no long-term follow-up data available on safety and effectiveness.
The mode and technique of delivery of stem cells was not compared in any of the studies. Dozois et al. reported higher healing rates when stem cells were combined with fibrin glue or impregnated on a Gore Bio-A Fistula Plug versus direct injection [71% and 83% vs. 50%] 39 . While allogeneic stem cell therapy may be an effective and safe approach to treat complex perianal fistula, patient selection, optimal mode of delivery, and dose and frequency of injections should be determined in further studies.
Statement 1.8 ECCO CD Treatment GL [2019]
Autologous adipose-derived stem cells may have positive effect for patients with
Crohn's disease and complex perianal fistulae with good tolerability and safety [EL4]
Autologous adipose-derived stem cells [ASC] have the advantage of originating from the patient considered for treatment, as opposed to donor-based therapy. Yet, both Last, a recent prospective study investigated the effects of injecting freshly collected autologous adipose tissue into perianal CD fistulas. Twenty-one patients were treated with repeat injections offered when no healing was observed at 6 weeks, or later relapse occurred. Six months following the last adipose tissue injection, 12/21 patients (57%) had complete fistula healing confirmed by MRI and AE were minimal 44 .
Harvesting, preparation, and administration of adipose tissue were performed as a single and inexpensive procedure. Further studies are required to define the true potential of this approach.
Key points for clinical practice
Complex perineal disease remains a challenging CD presentation. Innovative approaches, such as LIFT and stem cell-based treatment, have enriched the 
Statement 3.2 ECCO CD Treatment GL [2019]
Following successful image-guided drainage of an intra-abdominal abscess, medical management without surgery may be considered. A low threshold for surgery is recommended in the event that medical management is not successful [EL4] There is a limited evidence on the optimal management of CD patients with intraabdominal abscess who underwent PD. In particular, the optimal timing of surgical intervention after abscess drainage is unknown. Up to 30% of patients may avoid surgery following successful PD 52 . Identifying those who may be treated without further surgery is challenging and presently relies on clinical judgment rather than on evidence. Nevertheless, elective surgery should be considered after sepsis control/resolution by PD and antibiotic therapy, as abscess recurrence is up to 6.5 times greater following PD as stand-alone therapy than PD followed with surgical resection. Medically refractory disease, the presence of stenosis, or an enterocutaneous fistula, be it primary established or as a consequence of PD, increase the likelihood of surgery. Conversely, emergency surgery without prior PD and sepsis control is associated with a higher rate of complications and stoma than with initial PD followed by surgery 53 . Successful PD can be considered as a bridge to elective surgery, allowing nutritional and medical optimization and hence improved postoperative outcomes 3, 54 .
Key points for clinical practice
The control of intra-abdominal abscesses resembles the approach to pelvic sepsis with interventional radiology, infectious disease, gastroenterology, and surgery involved, together with nutritional support. Frequent monitoring and surgical consultation are critical. Fortunately, surgery can be deferred in most cases. Definitive non-surgical management may be successful but must be carefully balanced and discussed with the individual patient. 17 Treatment with 20 mg prednisolone daily or equivalent for > 6 weeks is an acknowledged risk factor for surgical complications and hyperglycaemia, as reported in prior ECCO guidelines 11, 18 . This has been extensively reported, although no large RCTs were dedicated to this issue. Two meta-analyses of prospective and retrospective cohort studies including 1714 IBD patients 58 and 3807 CD patients 59 reported up to a doubling of surgical site infections for patients on steroids. Cut-offs for increased surgical complications were observed between 10 mg and 40 mg prednisolone daily for more than 3-6 weeks together with a uniform recommendation of tapering down steroids whenever possible prior to surgery. Conversely, thiopurines can be safely continued perioperatively 7, 11, 18, [58] [59] [60] [61] [62] Lastly, little evidence supports the common practice of steroid stress dose administration perioperatively for patients on long-term corticosteroids over plain continuation of the preoperative dose, converted to intravenous equivalents where necessary 63 . Two small RCTs [37 patients] and five cohort studies [462 patients] did not demonstrate any benefit of steroid stress dose administration 64 . Testing of the hypothalamic-pituitary-adrenal axis can be considered on an individual basis to assess adrenal suppression 65 .
Statement 4.3 ECCO CD Treatment GL [2019]
Current evidence suggests that pre-operative treatment with anti-TNF therapy [EL3], vedolizumab [EL4], or ustekinumab [EL4] does not increase the risk of post-operative complications in patients with CD having abdominal surgery. Cessation of these medications prior to surgery is not mandatory
Anti-TNF therapy
The use of biologics in CD patients scheduled for surgery has been controversial.
Concern was raised that by modulating the immune response, biologics may increase surgical site infections and morbidity. Some recent guidelines still caution against the use of anti-TNF therapy in this context, however the safest period of omission remains unknown 11 . The most recent meta-analysis on this subject included 18 nonrandomized controlled studies with 1407 patients on infliximab and 4589 who were 66 . This was also true for reoperation and mortality considered alone or included into major complications. Finally, results from the PUCCINI RCT presented as an abstract at the 2019 Digestive Disease Week that included 955 IBD patients showed that exposure to anti-TNF therapy, including the measurement of drug levels, had no effect on the occurrence of any surgical site infection or anastomotic leak.
Vedolizumab
Early data, including a retrospective multicentre analysis, comparing the postoperative outcomes of 146 patients receiving vedolizumab versus 289 patients on anti-TNF therapy revealed a significantly increased rate of surgical site infections after abdominal surgery in patients on vedolizumab 67 . However, the most recent metaanalysis comparing 307 IBD patients treated with vedolizumab versus 490 patients on anti-TNF and 535 patients not exposed to preoperative biologic therapy revealed no differences in postoperative infectious and overall complications between vedolizumab patients and patients without biologic therapy [OR 0.99, resp. 1.00]. A similar outcome was observed when comparing patients on vedolizumab with those on anti-TNF therapy for the occurrence of postoperative infectious and overall complications [OR 0.99, resp. 0.92] 68 . Although larger, randomized studies including perioperative drug monitoring remain necessary, treatment with vedolizumab appears to be safe in the surgical context.
Ustekinumab
Two retrospective multicentre cohort studies compared CD patients exposed 19 therapy [25% vs. 2.5%; p = 0.01] 69 , and to be re-operated [16% vs. 5%; p = 0.01] 70 .
Nevertheless, no increase in early and late postoperative complications were noted in multivariate analysis when comparing the surgical outcomes of those 60 patients on ustekinumab versus 209 patients receiving anti-TNF therapy 69, 70 . Again, studies of better design and larger patient numbers are required to confirm these results.
Statement 4.4 ECCO CD Treatment GL [2019]
Preoperative control of sepsis is recommended prior to abdominal surgery for Crohn's 
Key points for clinical practice
Preoperative optimization is a key element in successful management of complex situations and chronic disease. Many aspects of optimal perioperative care are generic and common to all abdominal procedures 72 , although some aspects are particularly important in the context of CD [venous thromboembolism prophylaxis, nutrition, iron management, drug management, minimally invasive approaches, and bowel-and sphincter-sparing techniques] 54, 73 . A good relationship across disciplines and professions is critical. 75 . There were no differences in outcomes when primary or anastomotic strictures were dilatated. Recent observational studies revealed comparable results [76] [77] [78] [79] . Hence, balloon dilatation of both primary and anastomotic short CD strictures appears safe and effective in the short term. However, recurrence is the rule and the need for surgery is frequent in the following 5 years.
Section 5. Small-bowel obstruction
Statement 5.3 ECCO CD Treatment GL [2019]
Strictureplasty is a safe option to treat small bowel strictures related to Crohn's disease. Strictureplasty may be preferable to resection of long segments of bowel with potential reduction in surgical recurrence rates [EL3]
Strictureplasty is an established and safe surgical option for treating strictures related to CD and is an alternative to bowel resection 80, 81 . Strictureplasty is recommended whenever reasonable and technically feasible, particularly with multiple fibrotic strictures that would otherwise require more than a minimal bowel resection 11, 82 . A meta-analysis of 1112 patients who underwent 3259 strictureplasties [81% Heineke-Mikulicz, 10% Finney, 5% side-to-side isoperistaltic] prior to the biologic era revealed a 5-year recurrence rate of 28% 83 . Heineke-Mikulicz is the preferred technique for stenotic segments up to 6-8 cm, while Finney and side-to-side isoperistaltic techniques address longer or multiple strictures and require more expertise 84 . Surgical morbidity is in the range of 8-15% and is unrelated to stricture length 84, 85 . Favourable long-term results have been reported 81, 84, 85 and suggest better results for strictureplasty compared with resection. A large Japanese series reviewed 526 patients, of which 435 underwent only bowel resections and 91 had a total of 199 strictureplasties. At 10 years, the site-specific cumulative rate of reoperation was 18% at the anastomosis site versus 7% at the strictureplasty site [p < 0.01] 86 . 
Section 6. Surgical techniques for abdominal CD Statement 6.1 ECCO CD Treatment GL [2019]
Laparoscopic surgery should be offered as the first line approach in surgery for Crohn's disease dependent on appropriate expertise [EL2]
A meta-analysis and a Cochrane review of two RCTs 87,88 showed no statistical difference in any outcomes between laparoscopic and open surgery for small-bowel CD. A more recent meta-analysis, which included RCTs and observational studies, revealed fewer complications and fewer incisional hernias in favour of the laparoscopic approach 89 . A further meta-analysis assessed laparoscopic resection for recurrent CD, confirming feasibility and safety in the presence of appropriate expertise 90 . Conversion to open surgery was 2.5 times more frequent in this context, although complications did not increase. Hence, patients benefit from a laparoscopic approach in surgery for primary and recurrent small-bowel CD with fewer postoperative complications and 
Statement 6.5 ECCO CD Treatment GL [2019]
Stapled small-bowel or ileocolic side-to-side anastomoses are associated with lower rates of postoperative complications than end-to-end anastomoses in Crohn's disease
[EL3]
Technical aspects are important to surgeons and can be influenced by many factors, including prior training, personal experience, available resources, and clinical situation. 11 , particularly for the patient who has suffered an extensive loss of small bowel. In summary, the extent of colonic resection is indicated by the clinical situation [elective vs. emergency surgery] and the number of colonic segments involved. Segmental colectomy is preferred whenever possible.
Statement 6.7 ECCO CD Treatment GL [2019]
A defunctioning stoma for non-acute refractory Crohn's colitis may delay or avoid the need for colectomy [EL5]
The following two options may be discussed in the presence of refractory CD colitis: a (sub)total colectomy, particularly as a potentially life-saving procedure in fulminant colitis, and a defunctioning ileostomy to divert the faecal stream and allow for remission, together with intensified medical therapy 126 The literature prior to the biologic era reports initial remission rates of approximately 90% 45, [127] [128] [129] following creation of a defunctioning stoma, which is less than the 50-80% reported in more recent series 130, 131 . Lasting restoration of bowel continuity/stoma reversal was effective in up to two-thirds of the patients but was much less when perineal disease was also present [i.e. 29-42%] 130, 131 . Surgical complications of defunctioning stoma creation were in the expected range of 3-10% for stoma prolapse/hernia and < 5% renal failure due to high-output stoma 130 . Further bowel resection was reported in up to half of the patients in recent series 130, 131 . Risk factors for (procto)colectomy were severe refractory perineal disease, requirement for combined medical therapy, and a history of >1 biologic drug. For these patients, early colectomy and end ileostomy [as opposed to a defunctioning ileostomy] may be discussed.
Statement 6.8 ECCO CD Treatment GL [2019]
Restorative proctocolectomy with ileal pouch-anal anastomosis can be considered in Reese et al. 136 performed a meta-analysis of 3103 patients, of whom 225 were CD-IPAA and suffered from twice as many anastomotic strictures and six times more pouch failures [32% vs 4.8%, p < 0.01]. However, in patients with isolated colonic CD, no significant difference in postoperative complications or pouch failure [8% in CD-IPAA patients vs. 7.1% in UC-IPAA patients] was observed. Importantly, patients with isolated colonic CD did not have more complications or pouch failures than UC patients. Nevertheless, IPAA function was poorer in CD patients [two times more incontinence and urgency], although stool frequency did not differ. Similarly, no difference in quality-of-life scores were reported in the large Cleveland series, irrespective of the indication of IPAA 135 .
Conclusion
There are many options and crossroads in decision making for surgery in CD. Some approaches have been tested over time and were described in these surgical guidelines.
Although sufficient training, technical expertise, and an adequate caseload to achieve and maintain subspecialization in IBD surgery are important, the key to success in managing CD is a multidisciplinary team, as no specialist alone can solve the CD equation.
The present guidelines have been written with this interdisciplinary spirit in mind and summarize the current knowledge at hand. The degree of certainty in some aspects of surgery for CD is closer to eminence than evidence, thus paving the way for further research and better answers. Revealing gaps in evidence is the first step to resolution, as research focused on clinical needs and gaps in the current evidence will inform guideline updates. Meanwhile, dynamic integration of gains in knowledge into the ECCO e-Guide will allow for rapid dissemination. Guidelines provide guidance to the clinician, who adapt expert knowledge and generic evidence to individualize care. It is hoped that the present work will contribute to optimizing care for patients with CD. 
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